Ironwood Pharmaceuticals (IRWD) PT Raised to $16 at JPMorgan
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts IRWD Hot Sheet
Price: $3.50 +1.16%
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
11 Buy, 14 Hold, 2 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
JPMorgan analyst Eric Joseph raised the price target on Ironwood Pharmaceuticals (NASDAQ: IRWD) to $16.00 (from $13.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Citi Upgrades Ferrovial SA (FER:SM) (FRRVF) to Buy
- Aptiv PLC. (APTV) PT Lowered to $54 at Goldman Sachs
- Hybe Corporation (352820:KS) PT Lowered to KRW290,000 at Goldman Sachs
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
